Tiespectus clinical trials
Tiespectus is named as an intervention in 4 current clinical trials in our USA, UK, Spain, Australia, Germany, Poland, Switzerland, Mexico, Israel, France, Italy, Czechia, Portugal and Brazil registers. 4 are recruiting patients now. The most common phase is Phase 2/3. The sponsor with the most trials is EyeBiotech Ltd (2). The most-studied condition is Macular Degeneration.
Patient leaflets for Tiespectus
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Tiespectus
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Tiespectus
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| EyeBiotech Ltd | 2 |
| Merck Sharp & Dohme LLC | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Tiespectus trials
How many clinical trials are testing Tiespectus?
4 current trials in our USA, UK, Spain, Australia, Germany, Poland, Switzerland, Mexico, Israel, France, Italy, Czechia, Portugal and Brazil registers name Tiespectus (also registered as EYE201) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Tiespectus trials recruiting patients?
Yes. 4 of the 4 trials are recruiting: 4 with sites in USA, 2 with sites in UK, 2 with sites in Spain, 2 with sites in Australia, 1 with sites in Germany, 1 with sites in Poland, 1 with sites in Switzerland, 1 with sites in Mexico, 1 with sites in Israel, 1 with sites in France, 1 with sites in Italy, 1 with sites in Czechia, 1 with sites in Portugal and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Tiespectus clinical trials?
EyeBiotech Ltd (2) and Merck Sharp & Dohme LLC (2). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tiespectus works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tiespectus works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tiespectus (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.